Andrea Michelotti

Andrea Michelotti

Auto-generated profile, based on publicly available information

Andrea Michelotti

UO Oncologia Medica 1, Azienda Ospedaliero Universitaria Pisana, Ospedale S. Chiara, Pisa, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
PVPatrizia Vici
Patrizia Vici
LPLaura Pizzuti
Laura Pizzuti
CNClara Natoli
Clara Natoli
LMLUCA MOSCETTI
LUCA MOSCETTI
LMLucia Mentuccia
Lucia Mentuccia
TGTeresa Gamucci
Teresa Gamucci
Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted in selected patient populations, we performed a retrospective analysis of HER2-positive early breast cancer patients treated in the “pre-trastuzumab” and “trastuzumab” eras, with the aim to determine patients' outcomes in real-world practice. 925 consecutive HER2-positive breast cancer patients treated with adjuvant chemotherapy in ten Italian oncologic centers were identified. Patients who had received adjuvant chemotherapy alone (cohort A, 352 patients), and patients who had received adjuvant chemotherapy followed or combined with trastuzumab (cohort B, 573 patients) were analyzed. Relapse rate at 3 years, relapse-free survival, and overall survival were significantly more unfavorable in the cohort A than in the cohort B (p < 0.0001). In multivariate analysis, factors related to relapse were younger age, advanced stage at diagnosis, absence of hormonal and of trastuzumab therapy. The benefit derived from the addition of trastuzumab was independent of nodal status and hormonal receptors expression. A subgroup analysis including 163 “triple positive” tumors with high levels of estrogen and progesterone receptor (TP50) suggested that addition of trastuzumab to adjuvant chemotherapy and hormonal therapy did not translate into better outcomes. In our analysis, trastuzumab benefit was confirmed in all but a small subset of TP50 tumors subgroups. In this subset further investigations are needed.

1 January 2000 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
AMAndrea Michelotti
Andrea Michelotti
MVMarco Venturini
Marco Venturini
CTCarmelo Tibaldi
Carmelo Tibaldi
CBCarmelo Bengala
Carmelo Bengala
Luigi GalloLuigi Gallo
Luigi Gallo
Pierfranco ContePierfranco Conte
Pierfranco Conte

18 October 2022 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
RCRoberta Caputo
Roberta Caputo
AFAlessandra Fabi
Alessandra Fabi
EREmanuela Romagnoli
Emanuela Romagnoli
EBEditta Baldini
Editta Baldini
DGDonatella Grasso
Donatella Grasso
AMAndrea Michelotti
Andrea Michelotti
Male breast cancer (BC) is rare, globally constituting only 0.5– 1% of all patients with BC. In Italy, more than 2000 new male BC cases were registered between 2000 and 2014. The survival rate was lower in males than in females. Delayed diagnosis may be the reason for poorer outcome observed in male BC patients compared with female patients. Due to lack of substantial evidence and low availability of published data on male BC, the current treatment recommendations are based on evidence derived from trials on female patients. In Italy, most of the male BC patients are estrogen and progesterone receptor–positive. Targeted therapy in combination with endocrine therapy provides a clinically meaningful outcome in patients with hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2–negative (HER2-negative) advanced BC. CompLEEment-1 is a single-arm, open-label, multicenter, phase 3b trial investigating the safety and efficacy of a CDK4/6 inhibitor, ribociclib, in combination with letrozole in men and women. Herein, we report the results from a retrospective analysis of five Italian male patients who completed the core phase. In this case series, the combination of ribociclib and letrozole was well tolerated and appeared to be effective in the male cohort with HR-positive, HER2-negative advanced BC in Italy. CompLEEment-1 trial representative of a real-world setting would add value by supporting the existing efficacy and safety profile of ribociclib in combination with letrozole in male patients with HR-positive, HER2-negative advanced BC. ClinicalTrials.gov Registration Number: NCT02941926.